Axxcess Wealth Management LLC Decreases Position in IDEXX Laboratories, Inc. $IDXX

Axxcess Wealth Management LLC lowered its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 41.2% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,242 shares of the company’s stock after selling 869 shares during the quarter. Axxcess Wealth Management LLC’s holdings in IDEXX Laboratories were worth $794,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also modified their holdings of IDXX. Bank of New York Mellon Corp grew its stake in IDEXX Laboratories by 156.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 1,451,390 shares of the company’s stock worth $778,439,000 after purchasing an additional 884,808 shares in the last quarter. Generation Investment Management LLP acquired a new position in shares of IDEXX Laboratories during the second quarter worth about $304,277,000. Norges Bank acquired a new position in shares of IDEXX Laboratories during the second quarter worth about $221,955,000. JPMorgan Chase & Co. increased its stake in shares of IDEXX Laboratories by 60.0% during the third quarter. JPMorgan Chase & Co. now owns 869,930 shares of the company’s stock worth $555,802,000 after buying an additional 326,348 shares during the period. Finally, Schroder Investment Management Group raised its holdings in IDEXX Laboratories by 295.1% in the second quarter. Schroder Investment Management Group now owns 315,785 shares of the company’s stock valued at $169,368,000 after acquiring an additional 235,863 shares in the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Key IDEXX Laboratories News

Here are the key news stories impacting IDEXX Laboratories this week:

• Positive Sentiment: Analyst support remains a tailwind — multiple firms continue to rate IDXX favorably (Jefferies, BTIG, Barclays among others) and the consensus remains a “Moderate Buy” with a material above‑current price target consensus. That analyst backdrop can support buying interest. Read More.
• Neutral Sentiment: Company fundamentals: IDXX reported a slight EPS miss (by $0.01) for the most recent quarter but beat on revenue (+14% y/y) and provided FY‑2026 EPS guidance of $14.29–$14.80 — guidance is above many near‑term expectations, which is generally constructive for the stock. Read More.
• Neutral Sentiment: Re‑rating narrative: recent commentary (Conestoga/InsiderMonkey, Yahoo syndicated pieces) argues IDXX shares are re‑rating toward historical averages — this is discussion‑driven and could help multiple investors re‑allocate into the name if the argument gains traction. Read More.
• Neutral Sentiment: Comparisons in the sector: valuation/sector pieces (e.g., Zacks comparing SONVY vs IDXX) may influence relative‑value flows but don’t present new company‑specific catalysts. Read More.
• Neutral Sentiment: Short‑interest data posted for February appears to show zero shares / zero days‑to‑cover (likely a reporting anomaly). That suggests no clear short‑squeeze pressure at present but verify with exchange short‑interest releases.
• Negative Sentiment: Insider selling: multiple execs disclosed sizable sales on Feb 17 — Director Sophie Vandebroek sold 1,464 shares (~$628.62 avg) and EVP Michael Erickson sold 5,371 shares (~$627.38 avg). Large insider sales can be read as signal of personal liquidity/positioning and may weigh on near‑term sentiment. Read More. Read More.

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, EVP Michael G. Erickson sold 5,371 shares of the business’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $627.38, for a total value of $3,369,657.98. Following the completion of the sale, the executive vice president owned 12,693 shares in the company, valued at approximately $7,963,334.34. The trade was a 29.73% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Sophie V. Vandebroek sold 1,464 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $628.62, for a total transaction of $920,299.68. Following the transaction, the director owned 648 shares in the company, valued at approximately $407,345.76. This trade represents a 69.32% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 18,180 shares of company stock worth $11,626,996. 0.98% of the stock is owned by insiders.

IDEXX Laboratories Price Performance

Shares of IDXX opened at $635.66 on Friday. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.23 and a quick ratio of 0.90. IDEXX Laboratories, Inc. has a 1-year low of $356.14 and a 1-year high of $769.98. The stock has a market cap of $50.76 billion, a PE ratio of 48.64, a price-to-earnings-growth ratio of 3.87 and a beta of 1.67. The firm has a fifty day moving average price of $677.74 and a 200 day moving average price of $669.01.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Monday, February 2nd. The company reported $2.92 EPS for the quarter, missing analysts’ consensus estimates of $2.93 by ($0.01). The firm had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The firm’s revenue for the quarter was up 14.3% on a year-over-year basis. During the same quarter last year, the firm posted $2.53 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. As a group, sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Analysts Set New Price Targets

IDXX has been the subject of several analyst reports. UBS Group lowered their price target on shares of IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating for the company in a report on Tuesday, February 3rd. BTIG Research lowered their target price on shares of IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a research note on Tuesday, February 3rd. Morgan Stanley raised their price target on IDEXX Laboratories from $765.00 to $805.00 and gave the company an “overweight” rating in a research note on Tuesday, November 4th. Leerink Partners set a $785.00 price target on IDEXX Laboratories in a report on Monday, November 3rd. Finally, Weiss Ratings downgraded IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, January 29th. Seven analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $783.33.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.